Skip to main content
Assistant Professor of Pharmacy and Epidemiology, Assistant Director - Rutgers Center for Pharmacoepidemiology and Treatment Science, Academic Director - Rutgers Center for Health Outcomes, Policy, and Economics
Area of Study/Expertise
Pharmacoepidemiology, Health Outcomes, Health Service Research, Geriatrics, Diabetes, Cardiovascular Disease
Office Location
Pharmacy Practice and Administration
Phone Number
(848) 932-6940

Chintan Dave, PharmD, PhD

Core Faculty

Chintan Dave, a pharmacoepidemiologist and health economist, joined PETS and Ernest Mario College of Pharmacy in 2019 as an Assistant Professor of Pharmacy. He received his pharmacy degree from St. Louis College of Pharmacy (2012), his Ph.D. in Pharmacoepidemiology from University of Florida (2017) and post-doctoral training from Harvard Medical School (2019). He has conducted several observational studies on the comparative safety and effectiveness of pharmaceuticals. His recent work has focused on the safety and cardiovascular effectiveness of Sodium-glucose co-transporter-2 inhibitors, a newer class of agents used for the management of diabetes. Broadly, his work leverages large observational databases and applies advanced statistical and epidemiological methods for confounding adjustment, within the areas of cardiometabolic and geriatric pharmacoepidemiology. He has led projects that have culminated in first author publications in leading journals like the New England Journal of Medicine, Annals of Internal Medicine and JAMA: Internal Medicine. He is the Assistant Director for industry fellowships at PETS, and the Academic Director at the Rutgers Center for Health Outcomes, Policy, and Economics (HOPE). Currently, he serves as the PI of an R01 award from NHLBI and a research award from JDRF.

Research Profile
Pharmacoepidemiology, Health Outcomes, Health Services Research, Geriatrics, Diabetes, Cardiovascular Disease

Select Publications

  1. Dave CV, Li Y, Steinman M, Lee SJ, Liu X, Jing B, Graham LA, Marcum ZA, Fung K, Odden MC. Initiation of antihypertensives and risk of fractures among older VA nursing home residents. JAMA Internal Medicine. 2024 (in press).
  2. Dave CV, Brittenham GM, Carson JL, Setoguchi S. Risks for Anaphylaxis With Intravenous Iron Formulations : A Retrospective Cohort Study. Annals of Internal Medicine. 2022 May;175(5):656-664. doi: 10.7326/M21-4009. 2022 PMID: 35344378.
  3. Dave CV, Kim SC, Goldfine A, Glynn R, Tong A, Patorno E. Risk of Cardiovascular Outcomes in Patients with Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy. Circulation. 2021 Feb 23;143(8):770-779.
  4. Dave CV, Schneeweiss S, Wexler DJ, Brill G, Patorno E. Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013-2018. Diabetes Care.2020 Apr;43(4):921-924
  5. Dave CV, Schneeweiss S, Patorno E. Association of Sodium-Glucose Cotransporter 2 Inhibitor Treatment With Risk of Hospitalization for Fournier Gangrene Among Men. JAMA Internal Medicine. 2019 Sep 3;179(11):1587–90.
  6. Dave CV, Hartzema A, Kesselheim AS. Prices of Generic Drugs Associated with Numbers of Manufacturers. New England Journal of Medicine. 2017 Dec 28;377(26).
  7. Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E, Sodium-glucose cotransporter 2 inhibitors and the risk of severe urinary tract infection events. Annals of Internal Medicine 2019 Aug 20;171(4):248-256.
  8. Dave CV, Kesselheim AS, Fox ER, Qiu P, Hartzema A. High Generic Drug Prices and Market Competition: A Retrospective Cohort Study. Annals of Internal Medicine. 2017 Aug 1;167(3):145-151.

Select Trainee Led Publications

  1. Reynolds KR, Khosrow-Khavar F, Dave CV. Disparities in the uptake of direct acting oral anticoagulants for atrial fibrillation by race, ethnicity and social vulnerability among Medicare beneficiaries. JAMA: Network Open (in press).
  2. Henderson M, Horton DB, Bhise V, Pal G, Bushnell G, Dave CV. Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among U.S. Adults and Children, 2001-2020. JAMA Neurology. 2023
  3. Liaw J, Harhay M, Setoguchi S, Gerhard T, Dave CV. Trends in prescribing preferences for antidiabetic medications among type 2 diabetes patients in the UK with and without chronic kidney disease, 2006-2020. Diabetes Care. 2022. 45.10: 2316-2325.


February 2023 – January 2028
Evaluating the role of multimorbidity in modulating medication effects in older adults
National Heart, Lung, and Blood Institute (1R01HL16316301)
Principal Investigator

May 2023 – April 2025 

Preventing Suicide in Rural Veterans: Implementation of an Evidence-Based Telehealth Mindfulness Intervention

Subcontract PI to Rutgers, Biostatistician

August 2022 – July 2025
Predictors of Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes
Juvenile Diabetes Research Foundation (3-SRA-2022-1257-S-B)
Principal Investigator

March 2021 – April 2023
Neurocognitive markers of short-term risk for suicidal behavior in high-risk Veterans
Veterans Health Administration (I01CX001826)
Co-Investigator, Biostatistician

July 2019 – June 2021
Health outcomes of older adults dually diagnosed with type 2 diabetes and cardiovascular diseases
National Center for Advancing Translational Sciences (1KL2 TR003018)
Principal Investigator